Podcasts about diagnostic

Dr. Halley Alexander and Dr. Alissa M. D'Gama discuss genetic testing for infantile epilepsies.  Show citation:  Nguyen JNH, Lachgar-Ruiz M, Higginbotham EJ, et al. Diagnostic Yield of Comprehensive Reanalysis After Nondiagnostic Short-Read Genome Sequencing in Infants With Unexplained Epilepsy. Neurology. 2026;106(6):e214645. doi:10.1212/WNL.0000000000214645  Show transcript:  Dr. Halley Alexander:  Hi, this is Halley Alexander with today's Neurology Minute, and I'm here with Dr. Alissa D'Gama from Boston Children's Hospital and Harvard Medical School, and we just finished recording a full-length podcast about some exciting new work in genetic testing for infantile onset epilepsies. Alissa, can you tell us what you found briefly and why it's important for neurology care? Dr. Alissa D'Gama:  Infantile epilepsies are relatively common, and they're associated with substantial burden of disease, and we know that identifying underlying genetic causes can impact clinical care. It's important for emerging precision therapies. But even after genome sequencing, which is the most comprehensive clinical genetic testing currently available, most infants remain genetically unsolved. And so what we did was take that genome sequencing data and reanalyze it for a cohort of infants who had unexplained non-acquired epilepsy and non-diagnostic genome sequencing, and in about 5% of cases, our reanalysis was able to identify a genetic diagnosis, and all of these diagnoses had impact on clinical care for their infants and their families. In some cases, we could incorporate new information, either new clinical information about the patient or new scientific methods or information about disease associations, and in other cases, we were able to incorporate new analysis methods to identify variants. And so our findings suggest that implementing reanalysis for infants or any individual with epilepsy within a year or two of non-diagnostic testing may be useful. Dr. Halley Alexander:  Thank you so much, and you can find a lot more details by listening to the full-length podcast, which is available now on the Neurology podcast, and you can find the full article in the March 10th issue of Neurology or online at neurology.org. As always, thanks for tuning in for today's Neurology Minute. 

Episode 5: The Polymathic Crime/Murder Board | A Diagnostic for an Age Addicted to Verdicts . What if our biggest threat to justice isn't corruption or ignorance, but our addiction to certainty? . In an age of instant outrage, viral accusations, and premature conclusions, we confuse speed with truth and emotional relief with accountability. Verdicts arrive long before understanding does, and they feel righteous, even when they're wrong. . In this episode of The Polymathic Perspective, we step into a radically different posture. Not a verdict. A diagnostic. . Using the logic of an FBI murder board, this episode examines why the human nervous system rushes to conclusions, how identity hijacks inquiry, and why simplifying harm into heroes and villains so often protects the systems that produce it. . You'll explore: Why certainty is neurologically soothing, and epistemically dangerous How the Central Park Five exposed what happens when narrative speed outruns investigative discipline Why harm often looks like alignment, not deviation How proxy wars reveal invisible beneficiaries and misplaced accountability Why real change always carries cost, and why cost is the only reliable evidence How the Epstein files function as an epistemic stress test, not a list of verdicts . This episode will frustrate anyone looking for outrage, moral shortcuts, or clean villains. It's designed for listeners willing to sit with uncertainty long enough for truth to survive pressure. Because justice that can't withstand scrutiny isn't justice at all... It's theater. . If you're ready to trade certainty for coherence, and outrage for accuracy, this episode will change how you listen to everything that comes next. About The Polymathic Perspective Podcast . The Polymathic Perspective is a weekly practice for integrative thinkers, leaders, and curious minds who refuse to collapse complexity into comforting lies. Each episode examines how meaning, identity, incentives, and systems interact beneath the stories we're told. This is not a podcast for conclusions. It's a podcast for diagnostic clarity.

Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar and Dr. Peter Lio discuss significant advancements in dermatology, including the recent approval of an ICD 10 code for topical steroid withdrawal, the exploration of botanicals in skin treatment, and the emerging understanding of the gut-skin connection. They also delve into the role of GLP medications in managing skin conditions and the exciting future developments in dermatology, particularly in the treatment of atopic dermatitis. Read the referenced documents at the following sites: - Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy: https://doi.org/10.1016/j.jdrv.2025.12.008 - The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis: https://jintegrativederm.org/article/view/109 - Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+: https://www.medrxiv.org/content/10.1101/2024.04.17.24305846v1.full-text - Jennifer Fugo information: https://www.skinterrupt.com/book-a-session/ Takeaways - The CDC has approved an ICD 10 code for topical steroid withdrawal. - This approval allows for better study and understanding of TSW. - Diagnostic criteria for TSW are still being developed. - Topical steroid withdrawal may overlap with severe atopic dermatitis. - Non-steroidal treatments are becoming more prominent in dermatology. - Botanicals have been used across cultures for skin treatment. - The gut-skin connection is gaining attention in dermatology. - GLP medications may play a significant role in dermatological treatments. - The future of dermatology is promising with new treatments on the horizon. - A holistic approach to skin health is essential for effective treatment. Chapters 00:00 - Introduction to Dermatology Innovations 01:43 - Topical Steroid Withdrawal Breakthroughs 06:53 - Exploring Botanicals in Dermatology 09:15 - Gut-Skin Connection and Metabolic Health 13:42 - The Role of GLPs in Dermatology 19:42 - Future of Dermatology: Exciting Developments

Dr. Halley Alexadner talks with Dr. Alissa M. D'Gama about genetic testing for infantile epilepsies.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

Pastors don't start cynical or burned out. But somewhere along the way, the wine runs out and we keep preaching, leading, and carrying burdens we were never meant to carry.In a Practically Pastoring Conference session, Tim Wildsmith walks through John 2:1–11 and connects it with Matthew 11:28–30, offering a simple but piercing invitation: name the need, surrender the burden, and pursue soul rest in Jesus before ministry emptiness turns into something worse.Follow Tim Wildsmith:Website: https://timwildsmith.comYouTube: https://www.youtube.com/@timwildsmithInstagram: https://www.instagram.com/timwildsmithX: https://x.com/timwildsmithFacebook: https://www.facebook.com/TimWildsmith/Timestamps:00:00 – Tim's story (Belmont, YouTube, Bible nerd life)03:44 – Why this talk (ministry grind, running on empty)05:42 – Reading: John 2:1–11 (Wedding at Cana)08:02 – When the wine runs out (ministry parallels)10:29 – Mary's model: “They have no more wine” (name the need)12:57 – Burnout realities + overwhelming expectations15:28 – Matthew 11:28–30: where do you go for rest?19:23 – The “rock” exercise: why we don't want to set burdens down22:12 – What is the soul? (Dallas Willard) + “rest for your souls”25:12 – Take His yoke: you can't wear both yokes27:23 – Back to John 2: obedience makes space for Jesus to work29:10 – Production vs. obedience (faithfulness, not self-sufficiency)30:04 – Diagnostic questions: where has the wine run out?32:07 – Practical step: name the need (even hard conversations)36:24 – Prayer for peace, surrender, and courageLinks:

Dr. Nyree Whitley, Chief Clinical Officer at mydentist & Dr. Gordon Barfield, Senior Clinical Manager at Overjet discuss: What a clinician-first diagnostic strategy looks like The dental regulatory & clinical environment in the UK Advice for clinical leaders evaluating AI in dentistry Much more To learn more about Overjet AI you can visit https://www.overjet.com/ and book a demo or connect with Dr. Barfield on Linkedin - https://www.linkedin.com/in/gordon-barfield-dds-ms-676a9516/ To learn more about mydentist you can visit https://www.mydentist.co.uk/ or connect with Dr. Whitley on Linkedin - https://www.linkedin.com/in/nyree-whitley-2a85b85a/  Subscribe to our channel for more episodes and stay updated on the latest DSO news, insights, and events! If you like our podcast, please give us a ⭐⭐⭐⭐⭐ review on iTunes https://apple.co/2Nejsfa and a Thumbs Up on YouTube.  

Dans cet épisode de Cheminements, nous plongeons au cœur de l'urgence absolue : la méningite. Cette infection foudroyante, qui peut toucher n'importe qui sans prévenir, impose une course contre la montre où le diagnostic précoce est la seule clé pour éviter le décès ou des séquelles irréversibles. À travers le récit bouleversant d'une mère devenue présidente d'association et l'expertise d'un infectiologue, nous explorons comment la collaboration entre patients et soignants sauve des vies et comment les nouvelles technologies diagnostiques transforment la prise en charge à l'hôpital.Les intervenants :Patricia Merhant-Sorel : Présidente de l'association Petit Ange (Ensemble contre la méningite). Après avoir perdu sa fille Gwendoline en 2003, elle consacre son action à l'accompagnement des familles et à la sensibilisation du public et des professionnels de santé.Docteur Nicolas Ettahar : Infectiologue au Centre Hospitalier de Valenciennes. Expert de la réalité clinique des maladies infectieuses, il apporte son regard sur les enjeux de diagnostic et de prévention.Les sujets abordés dans l'épisode :Le témoignage de Patricia sur la perte brutale de sa fille et la création de l'association Petit Ange.Les formes fulgurantes de la maladie : pourquoi l'évolution peut être fatale en moins de 12 heures.L'importance capitale du diagnostic différentiel face à des symptômes parfois trompeurs (fièvre, maux de tête).L'apport des tests rapides (PCR) pour cibler immédiatement le bon traitement antibiotique.Le rôle de la vaccination et des mesures barrières dans la prévention collective.La nécessité d'un dialogue permanent entre les familles, les cliniciens et les industriels du diagnostic.Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode est enregistré dans le cadre de la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui aura lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que cette journée s'écoutera aussi ! Des épisodes exclusifs du podcast Cheminements seront enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui viendront raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What if one of the biggest predictors of falls, balance issues, and even athletic decline wasn't the hips, core, or knees, but the toes? And what if strengthening them could dramatically change outcomes as we age? In this episode, I sit down with Dr. Tom Michaud, a chiropractor, researcher, and internationally recognized expert in foot biomechanics, to explore how weak toes and poor foot function significantly increase fall risk in older adults and limit performance in master athletes. We discuss why foot and ankle health is often overlooked and how it serves as the foundation for balance, speed, and long-term vitality. Dr. Michaud breaks down findings from pivotal studies, including work by researchers like Karen Mickle and Max Piquet, highlighting the role of intrinsic foot muscles such as the flexor hallucis longus and peroneus longus in stability and dynamic movement. We also cover simple at-home tests to assess fall risk and practical exercises that actually improve foot strength. This episode is essential listening for clinicians, athletes, and anyone who wants to stay mobile, resilient, and active as they age.   Key takeaways: Weak toes are a primary predictor of falls in older adults, leading to serious injuries and complications. Enhancing toe strength through targeted exercises can significantly reduce fall risk while boosting athletic performance. Not all traditional foot exercises are effective - exercising the foot muscles in a lengthened position yields better strength gains. Proper assessment of foot architecture and the application of custom strengthening exercises can prevent injuries and improve dynamic performance. Diagnostic tests like the anterior fall envelope and paper grip tests offer valuable insights into an individual's fall risk and foot strength.   More About Dr. Tom Michaud:   In the early nineties, Williams and Wilkins published Dr. Michaud's first textbook, Foot Orthoses and Other Forms of Conservative Foot Care, which was eventually translated into four languages. His next book, Human Locomotion: The Conservative Management of Gait-Related Disorders, which was published in 2012, is used in physical therapy, chiropractic, pedorthic, and podiatry schools around the world. In addition to technical books, Tom also published a book for recreational runners: Injury-Free Running: How to Build Strength, Improve Form, and Treat/Prevent Injuries, now in its second edition. During his 40 years of clinical practice, Dr. Michaud designed and patented numerous diagnostic tools and exercise products to help with the evaluation and treatment of a wide range of sports injuries. Since his recent retirement from clinical practice, Tom is devoting his time to researching, writing, and designing new products in order to develop evidence-based evaluation and treatment protocols that can assist in not just the prevention of sports injuries, but also in ways to stay fit as we age.   Website Instagram Connect with me! Website Instagram Facebook YouTube

"Isolate the Real It: The Diagnostic Approach to Closing More Sales"You didn't lose that sale because of price, product, or timing. You lost it because you never isolated the Real It—the actual thing standing in the way. Most salespeople try to solve everything at once, overwhelming the homeowner and killing the sale before it ever had a chance.In this episode, Sam Wakefield breaks down the diagnostic approach to sales that separates top performers from everyone else. You'll learn how to use qualification questions—not to qualify the homeowner, but to isolate the components of their decision. When you stop guessing and start diagnosing, you close more sales with less resistance.If you've ever walked away from an appointment confused about what went wrong, this episode will show you exactly how to find the Real It and guide your homeowner to clarity. This is the mental shift that changes everything.In This Episode:Why most salespeople lose sales by trying to solve the wrong problemThe combination lock metaphor: how one misaligned piece blocks the entire saleHow to use qualification questions to separate product, payment, timeline, and scopeReal-world language examples of isolating the Real It in appointmentsWhy confidence looks like clarity, not information overloadThe difference between diagnosing and convincingHow to get commitment before you negotiateWhy you can't negotiate with confusion—only clarityResources & Mentions:Win-Win Selling by Doug C. Brown (origin of "the Real It" language)Close It Now Coaching: closeitnow.net/coachingClose It Now Facebook Group: facebook.com/groups/closeitnowEmail Sam: sam@closeitnow.netNew Group Coaching Program:Sam is opening his first group coaching program starting March 2026. Pods of 5 salespeople focused on multiplying close rates and average tickets with integrity. Half the cost of one-on-one coaching. Limited to 5 spots per group. Visit closeitnow.net or email sam@closeitnow.net to learn more.Final Thought:A problem that is well-defined is half-solved. The next time a homeowner hesitates, don't panic. Don't pile on more information. Don't assume what's wrong. Just isolate the Real It. Ask the question that separates the pieces. Find the number that's off on the combination lock. And help them see it clearly. That's when the sale happens.Next Week:How to Right-Size a Project Without Discounting Your Price—the skill that protects your margin while keeping the sale alive.Leave a review on Apple Podcasts or Google to help more salespeople find this show.Google Review Link: https://g.page/r/CbfnnDqTCwQdEAE/review

Le diagnostic de performance énergétique est devenu un critère central dans l'immobilier. Mais à quoi sert-il vraiment ?Dans cet épisode de Perspective, Kamel Bahaj, expert en immobilier, décrypte le DPE et explique ce que signifient les différentes classes énergétiques, de A à G.Il revient sur l'impact du diagnostic énergétique sur la valeur d'un bien, sur les possibilités de location, sur le financement bancaire, ainsi que sur les travaux à anticiper dans l'ancien.Un épisode pour comprendre pourquoi le DPE est aujourd'hui un véritable outil d'aide à la décision, que l'on achète pour y vivre ou pour investir.PERSPECTIVE, c'est le podcast qui permet de comprendre l'habitat d'aujourd'hui et d'imaginer celui de demain. De l'achat d'un logement aux manières de l'habiter, de nombreuses questions peuvent survenir. Des experts vous répondent et vous partagent leurs recommandations et conseils pratiques.PERSPECTIVE est un podcast de BOUYGUES IMMOBILIER produit par l'agence Calliopé.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Qu'est-ce que l'hyperparathyroïdie primitive et quels en sont les principaux mécanismes physiopathologiques ? Quelles sont les anomalies biologiques associées à cette pathologie ? Quelles sont les indications opératoires actuelles selon les recommandations ? Quelle est la place de l'imagerie et des traitements anti-ostéoporotiques dans la prise en charge ?Le Dr Eugénie Koumakis, rhumatologue à l'Hôpital Cochin, nous éclaire à ce sujet.Notre invitée déclare ne pas avoir de lien d'intérêt en rapport avec le sujet traité.L'équipe :Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret, Dr Roba Ghossan.Animation : Marguerite de RodellecProduction : MedShake StudioSoutien institutionnel : Pfizer

Episode spécial : Maladie Rare - Horizon hATTR n°2 « Amylose hATTR : Une filière structurée, un diagnostic partagé ». Invitée :Dr Céline Tard, neurologue au CHU de Lille et coordonnatrice du centre de référence des maladies neuromusculaires Nord-Est Île-de-France de la filière Filnemus. https://www.chu-lille.fr/services/centre-de-reference-des-maladies-neuromusculaires/https://www.filnemus.fr/ 1️⃣  Pourquoi participer au projet « Horizon hATTR » ? [0'38 – 2'23] ✔️ Valoriser l'expertise historique et pluridisciplinaire du CHU de Lille dans l'amylose.✔️ Mettre en lumière l'importance des RCP et de la multidisciplinarité dans l'hATTR.✔️ Sensibiliser et diffuser l'information sur les maladies rares via la filière Filnemus.2️⃣ Comment la revue Horizon améliore-t-elle la visibilité des actions du centre de référence du CHU de Lille ? [2'24 – 3'43] ✔️ Met en valeur l'expertise collective et transversale du centre.✔️ Renforce la visibilité des actions auprès des équipes et des patients.✔️ Accroît le rayonnement du CHU de Lille en interne et auprès d'autres centres.3️⃣ Quels aspects de votre collaboration lors de la création de la revue Horizon ont été particulièrement enrichissants ? [3'44 –4'26]✔️ Structurer une vision commune et hiérarchiser les priorités du centre.✔️ Valoriser les spécificités et l'expertise du centre de référence.✔️ Ouvrir des perspectives d'amélioration et de projets futurs.4️⃣ Dans quelle mesure d'autres filières de santé ou centres experts pourraient-ils collaborer avec RARE à l'écoute pour développer des revues Horizon et valoriser leurs initiatives ? [4'27 – 4'58] ✔️ Se lancer sans hésiter : la collaboration avec RARE à l'écoute est fluide et agréable.✔️ Profiter de supports de qualité, accessibles et bien vulgarisés pour valoriser les initiatives. L'équipe :Virginie Druenne – Ambassadrice RARE à l'écouteCyril Cassard – Journaliste/AnimationHervé Guillot - ProductionCrédits : Sonacom-------------------------------------------------------------------------------------------------------------------------RARE à l'écoute est le 1er média d'influence entièrement dédié aux maladies rares :- Un podcast pour faire entendre les voix de celles et ceux qui vivent, soignent et accompagnent ces maladies souvent invisibles.- Les Revues Horizon pour mettre en lumière les meilleures initiatives des centres experts, pour inspirer et connecter les professionnels de santé.- Des Lives engagés, pensés pour les patients, leurs proches et les associations.Un média indépendant, engagé et utile, au service d'un meilleur parcours de soin pour les patients atteints de maladies rares.Toutes nos ressources utiles sont accessibles gratuitement sur : www.rarealecoute.com

Eliot Deval revient pendant deux heures, sans concession, sur tous les sujets qui font l'actualité. Vous voulez réagir ? Appelez le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur les grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Échec scolaire, coming out tardif, hypersensibilité… Anthony Bapkine a longtemps porté des cadenas qui l'empêchaient d'avancer. Aujourd'hui, il est auteur, ex-chroniqueur BFM Business, entrepreneur social et fondateur de Diversidays, une association qui aide ceux qu'on a trop souvent mis de côté à se révéler dans le monde du travail.Il est éaglement le host du podcast Prends ta place qui partage des histoires positives de héros du quotidien.Dans cette premiere partie de l' épisode, Anthony revient sur son parcours non linéaire : du quartier Jean Rostand d'Évry à la signature de son premier livre chez Eyrolles à 20 ans, de ses premiers plateaux télé à sa sélection par la Obama Foundation où il a rencontré Barack Obama en petit comité. Il parle sans filtre de ce qui le freinait et de comment il a tout transformé en force.On aborde ensemble : l'imposture quand on est transfuge de classe, le poids du secret en entreprise quand on est LGBT, les discriminations invisibles liées aux origines sociales, le diagnostic tardif de l'hypersensibilité, et pourquoi se connaître soi-même est la clé pour aider les autres.

Tired of watching deals drag on for months while your pipeline stalls and your confidence tanks?Here's the truth most consultants miss: you're the one slowing down your own sales cycle.In this episode, Melisa reveals the four strategies that help consultants close deals faster without discounting, settling, or feeling "salesy."You'll discover why corporate buyers aren't actually the problem (even though it feels that way), and how the delays, stalls, and endless "I'll get back to you” responses are often triggered by how you're showing up in the sales process.This episode dismantles the myth that corporate buyers are always slow and instead puts the focus back on you as the expert, guiding, recommending, and leading your prospects toward clarity and action.Episode Timestamps:[06:01] Why long sales cycles are usually consultant-created and what to do about it[08:23] The Expert Mindset and how certainty speeds up decisions[18:02] The Foot-in-the-Door Offer strategy to generate revenue faster[25:08] How co-creating proposals with your buyer reduces delays and revisions[31:17] The Account Plan and how to stop winging your sales efforts[38:46] 6 questions to self-diagnose where your sales process needs workWhat you'll learn:The hidden consultant behaviors that extend your consulting sales cycle by weeks or even monthsHow to accelerate B2B sales without being pushy or compromising your valuePractical strategies to reduce proposal rework and rescoping delaysHow to lead the buying process with confidence and clarityWhy adopting an expert mindset shortens decision timelinesHow to diagnose and fix weak points in your sales processTopics covered: sales cycle management, consulting business development, B2B sales strategies, client acquisition for consultants, shortening sales timelines, proposal management, consulting sales process, expert positioningStop losing deals to delay. Listen to Episode 256 now and take back control of your sales timeline before another month slips by.Mentioned ResourcesCompanion Resource: Read Chapter 10 in Melisa's book, Grow Your Consulting Business: The 14-Step Roadmap to Make Your Independent Consulting Goals a Reality, https://www.amazon.com/dp/B0CSXJBGVB    Full Show Notes: https://shownotes.melisaliberman.com/episode-256Melisa's Books, Planners & Journals: https://linktr.ee/melisalibermanMentioned in this Episode: Episode 159 - Shorten the Consulting Sales Cycle by Offering a Diagnostic, https://shownotes.melisaliberman.com/episode-159/#more-2340 Want help achieving your consulting business goals? Melisa can help. Click here for more on coaching tailored to you as an independent consulting business owner.

Wayne Broman of Boeck Farm Outfitters has been helping growers with Precision Planting equipment since Cleansweep hit the market. In this episode, he tells Hans and Tyler the story about one of the most difficult troubleshooting scenarios he has come across.

In this episode, Dr Roger Henderson looks at adhesive capsulitis, commonly known as a frozen shoulder, reviewing its epidemiology, risk factors and underlying pathophysiology, as well as typical clinical presentations, disease staging and key examination findings that aid diagnosis in primary care. Diagnostic challenges, differential diagnoses and the role of imaging and injections are covered, alongside management strategies, prognosis and indications for surgical intervention, with particular attention to patients with diabetes and endocrine disorders who experience more severe and prolonged disease.Access episode show notes containing key references and take-home points at:https://gpnotebook.com/en-GB/podcasts/musculoskeletal-medicine/ep-192-adhesive-capsulitis.Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more.

Functional Neurological Disorder (FND) is often misunderstood... but it's real, common, AND treatable. In this episode of Talk Dizzy To Me, vestibular physical therapists Dr. Abbie Ross, PT, NCS and Dr. Carly Lochala, PT, NCS sit down with Dr. Julie Hershberg, PT, NCS to explain what FND is, why it's been minimized in healthcare, and how it overlaps with dizziness, migraine, dysautonomia/POTS, hypermobility/EDS, and vestibular disorders.They break down brain networks like the default mode network and salience network, discuss common clinical clues (variability, attention-related shifts), and explain how treatment often starts with nervous system regulation, trust-building, and whole-person care—not just exercises.If you've been told your symptoms are “all in your head,” this episode is for you.Guest: Dr. Julie Hershberg / Reactive PT Instagram: @reactiveptResources: FND resources hub, reactivept.com/FNDresourcesHosted by:

How can healthcare professionals transform burnout and trauma into a revitalized life and practice?In this special episode of Heartline: Changemaking in Healthcare, Dr. Andrea Austin reads from her book Revitalized, focusing on the chapter "The Revitalization." She reflects on her own soul-level burnout at the end of the pandemic, sharing a formula for change: inflection point + inner work + clarity = revitalization. Drawing from personal experiences and expert insights, she emphasizes embracing the past's pain as part of growth, avoiding trauma loops, and intentionally "doing the work" for self-improvement.You'll hear how to:Recognize burnout as a chronic issue requiring inner reflection, not just quick fixes, and frame it as an opportunity for revitalization beyond "bouncing back."Differentiate top-down therapies (like CBT and talk therapy) from bottom-up approaches (like EMDR, somatic experiencing, and art therapy) for trauma healing, especially in high-stress fields like medicine.Understand coaching as a future-focused partnership for unlocking potential, while knowing when to seek therapy first, given high rates of PTSD (40%) and depression (30%) among healthcare workers.Navigate "VUCA" (volatility, uncertainty, complexity, ambiguity) in healthcare, including life quakes like job loss or health crises, and avoid maladaptive coping like overconsumption or addictions.Build vulnerability in hard conversations, reflect on perfectionism, and beware predatory coaching programs while prioritizing ethical, supportive resources.If you're a healthcare professional grappling with burnout, trauma, or the desire for more fulfillment, this episode offers empathetic guidance, reflective questions, and actionable steps to craft your own revitalization.

In this episode, Dr. Erica Lacher and show host Justin Long talk about the wide variety of diagnostic tools that veterinarians use, what information they provide, and how veterinarians decide the best diagnostic options on a limited budget. Topics include imaging, blood tests, and more!

Le trouble bipolaire est une maladie psychiatrique qui se caractérise par des troubles de l'humeur, les personnes touchées pouvant alterner entre phases d'euphorie et épisodes dépressifs. Selon l'OMS, environ 1 adulte sur 150 dans le monde vivait avec ce trouble en 2019. S'il est possible de le réguler avec des traitements, les difficultés à le diagnostiquer entrainent des retards de prise en charge. Comment expliquer que le retard de diagnostic soit fréquent pour les patients atteints de troubles bipolaires ? Qu'est-ce qui peut motiver l'hospitalisation d'un patient atteint de trouble bipolaire ?  Pr Chantal HENRY, professeur de psychiatrie à l'Université de Paris, psychiatre au centre hospitalier de Sainte-Anne et chercheuse au sein de l'unité Perception et action à l'Institut Pasteur, Présidente du conseil scientifique de la Fondation Pierre Deniker (Rediffusion) Retrouvez l'émission en entier ici : Le trouble bipolaire  

When your child survives one medical emergency only to face another, parenting becomes a constant act of advocacy and courage. Today's guest joins us to share her daughter's journey with rare and complex medical conditions, from early respiratory failure and unexplained hospitalizations to epilepsy, lung disease, and life with medical uncertainty. As a military spouse navigating deployments, Brittany shares what it means to walk this path largely alone, trust her instincts as a mother, and fight to be believed by medical professionals. This episode explores navigating rare disease without clear answers, the life-changing impact of compassionate child life support, supporting siblings through medical trauma, and how rituals, play, and community help families find hope and meaning in the midst of chaos. Download our free Children's Hospital Passport to help empower your child and family during hospital stays. Sponsored in part by HealthWell Foundation—learn how you can help families afford life-saving medications at healthwellfoundation.org.   Resources from today's episode: Medical Support:  Stanford Children's Health  Undiagnosed Diseases Network Nonprofit & Community Support: Live Like JoJo Foundation The Meg Foundation (Pediatric Pain & Poke Plans)  Brave Bears Club (Epilepsy Support) Child Life Mommy CHYP  Connect with Brittany Follow Brittany's journey as she shares life as a medical mom, military spouse, and advocate.    Connect & Support from Child Life On Call  Subscribe: Never miss an episode on Apple Podcasts or Spotify. Visit insidethechildrenshospital.com to easily search stories and episodes Follow us on Instagram for updates and opportunities to connect with other parents Download SupportSpot: receive Child Life tools at your fingertips. Leave a Review: It helps other families find us and access our resources!   Keywords: Rare disease parenting, Medical motherhood, Medically complex child, Pediatric lung disease, Pediatric epilepsy, Intractable epilepsy, PICU parent experience, Military family healthcare, Parent advocacy in healthcare, Child life specialist support, Sibling support during hospitalization, Parenting after medical trauma, Coping with chronic illness, Undiagnosed disease journey, Hospital parent support Medical information provided is not a substitute for professional advice—please consult your care team  

In this special episode, recorded live at the 2025 Genomics England Research Summit, host Adam Clatworthy is joined by parents, clinicians and researchers to explore the long, uncertain and often emotional journey to a genetic diagnosis. Together, they go behind the science to share what it means to live with uncertainty, how results like variants of uncertain significance (VUS) are experienced by families, and why communication and support matter just as much as genomic testing and research. The panel discuss the challenges families face when a diagnosis remains out of reach, the role of research in refining and revisiting results over time, and how collaboration between researchers, clinicians and participants could help shorten diagnostic journeys in the future. Joining Adam Clatworthy, Vice-Chair for the Participant Panel, on this episode are: Emma Baple – Clinical geneticist and Medical Director, South West Genomic Laboratory Hub  Jamie Ellingford – Lead genomic data scientist, Genomics England  Jo Wright – Member of the Participant Panel and Parent Representative for SWAN UK  Lisa Beaton - Member of the Participant Panel and Parent Representative for SWAN UK  Linked below are the episodes mentioned in the episode:  What is the diagnostic odyssey?  What is a Variant of Uncertain Significance?  Visit the Genomics England Research Summit website, to get your ticket to this years event. You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes. My name is Sharon Jones and today we're bringing you a special episode recorded live from our Research Summit held in June this year. The episode features a panel conversation hosted by Adam Clatworthy, Vice-Chair of the Participant Panel. Our guests explore navigating the diagnostic odyssey, the often-complex journey to reaching a genetic diagnosis. If you'd like to know more about what the diagnostic odyssey is, check our bitesize explainer episode, ‘What is the Diagnostic Odyssey?' linked in the episode description. In today's episode you may hear our guests refer to ‘VUS' which stands for a variant of uncertain significance. This is when a genetic variant is identified, but its precise impact is not yet known. You can learn more about these in another one of our explainer episodes, “What is a Variant of Uncertain Significance?” And now over to Adam. -- Adam: Welcome, everyone, thanks for joining this session. I'm always really humbled by the lived experiences and the journeys behind the stories that we talk about at these conferences, so I'm really delighted to be hosting this panel session. It's taking us behind the science, it's really focusing on the people behind the data and the lived experiences of all the individuals and the families who are really navigating this system, trying to find answers and really aiming to get a diagnosis – that has to be the end goal. We know it's not the silver bullet, but it has to be the goal so that everyone can get that diagnosis and get that clarity and what this means for their medical care moving forwards.    So, today we're really going to aim to demystify what this diagnostic odyssey is, challenging the way researchers and clinicians often discuss long diagnostic journeys, and we'll really talk about the vital importance of research in improving diagnoses, discussing the challenges that limit the impact of emerging research for families on this odyssey and the opportunities for progress. So, we've got an amazing panel here. Rather than me trying to introduce you, I think it's great if you could just introduce yourselves, and Lisa, I'll start with you. Lisa: Hi, I'm Lisa Beaton and I am the parent of a child with an unknown, thought to be neuromuscular, disease. I joined the patient Participant Panel 2 years ago now and I'm also a Parent Representative for SWAN UK, which stands of Syndromes Without A Name. I have 4 children who have all come with unique and wonderful bits and pieces, but it's our daughter who's the most complicated. Adam:  Thank you. Over to you, Jo. Jo:  Hi, I'm Jo Wright, I am the parent of a child with an undiagnosed genetic condition.  So I've got an 11-year-old daughter. 100,000 Genomes gave us a VUS, which we're still trying to find the research for and sort of what I'll talk about in a bit.  And I've also got a younger daughter. I joined the Participant Panel just back in December. I'm also a Parent Rep for SWAN UK, so Lisa and I have known each other for quite a while through that. Adam:  Thank you, Jo.  And, Jamie, you're going to be covering both the research and the clinician side and you kind of wear 2 hats, so, yeah, over to you. Jamie:  Hi, everyone, so I'm Jamie Ellingford and, as Adam alluded to, I'm fortunate and I get to wear 2 hats. So, one of those hats is that I'm Lead Genomic Data Scientist for Rare Disease at Genomics England and so work as part of a really talented team of scientists and engineers to help develop our bioinformatic pipelines, so computational processes. I work as part of a team of scientists and software engineers to develop the computation pipelines that we apply at Genomics England as part of the National Health Service, so the Genomic Medicine Service that families get referred to and recruited to, and we try to develop and improve those. So that's one of my hats. And the second of those is I am a researcher, I'm an academic at the University of Manchester, and there I work really closely with some of the clinical teams in the North West to try and understand a little bit more about the functional impact of genomic variants on kind of how things happen in a cell. So, we can explore a little bit more about that but essentially, it's to provide a little bit more colour as to the impact that that genomic variant is having. Adam: Great, thank you, Jamie. Over to you, Emma. Emma: My name's Emma Baple, I'm an academic clinical geneticist in Exeter but I'm also the Medical Director of the South West genomic laboratory hub, so that's the Exeter and Bristol Genomics Laboratory. And I wear several other hats, including helping NHS England as the National Specialty Advisor for Genomics. Adam: Thank you all for being here. I think it's really important before we get into the questions just to ground ourselves in like those lived experiences that yourself and Jo and going through. So, Lisa, I'm going to start with you. The term ‘diagnostic odyssey' gets bandied around a lot, we hear about it so many times, but how does that reflect your experience that you've been through and what would you like researchers and clinicians to understand about this journey that you're on, essentially? Lisa: So I think ours is less an odyssey and more of a roller-coaster, and I say that because we sort of first started on a genetic journey, as it were, when my daughter was 9 weeks of age and she's now 16½ – the half's very important – and we still have no answers. And we've sort of come a bit backwards to this because when she was 6 months old Great Ormond Street Hospital felt very strongly that they knew exactly what was wrong with her and it was just a case of kind of confirmation by genetics. And then they sent off for a lot of different myasthenia panel genes, all of which came back negative, and so having been told, “Yes, it's definitely a myasthenia, we just need to know which one it is,” at 4 years of age that was removed and it was all of a sudden like, “Yeah, thanks, sorry.” And that was really hard actually because we felt we'd had somewhere to hang our hat and a cohort of people with very similar issues with their children, and then all of a sudden we were told, “No, no, that's not where you belong” and that was a really isolating experience. I can remember sort of saying to the neuromuscular team, “Well is it still neuromuscular in that case?” and there was a lot of shrugging of shoulders, and it just…  We felt like not only had we only just got on board the life raft, then we'd been chucked out, and we didn't even have a floaty. And in many ways I think I have made peace with the fact that we don't have a genetic diagnosis for our daughter but it doesn't get easier in that she has her own questions and my older children – one getting married in August who's already sort of said to me, you know, “Does this have implications for when we have children?”  And those are all questions I can't answer so that's really hard. Adam:  Thank you, Lisa. Yourself, Jo, how would you describe the odyssey that you're currently experiencing? Jo: So my daughter was about one when I started really noticing that she was having regressions. They were kind of there beforehand but, I really noticed them when she was one, and that's when I went to the GP and then got referred to the paediatrician. So initially we had genetic tests for things like Rett syndrome and Angelman syndrome, which they were all negative, and then we got referred on to the tertiary hospital and then went into 100,000 Genomes. So we enrolled in 100,000 Genomes at the beginning of 2017, and we got our results in April of 2020, so obviously that was quite a fraught time. Getting our results was probably not as you would want to do it because it was kind of over the phone and then a random letter. So, what I was told in that letter was that a variant of uncertain significance had been identified and they wanted to do further research to see if it might be more significant. So we were to be enrolled into another research project called Splicing and Disease, which wasn't active at the time because everything had been put on hold for COVID, but eventually we went into that. So, I didn't know what the gene was at that point, when I eventually got the form for going to get her bloods done…  So that went off and then that came back and the geneticist said, “That gives us some indication that it is significant.” So, since that point it's been trying to find more information and research to be able to make it a diagnosis. There have been 2 sort of key things that have happened towards that but we're still not there. So one of the things is that a research paper came out earlier this year so that's kind of a little bit more evidence, it's not going to give us a diagnosis but it kind of, you know, sits there. And the other thing is that my geneticist said, “Actually, yeah, it looks like it's an important change.”  That's as far as we've got. So we've still got work to do to make it a diagnosis or not.  Obviously if it is a diagnosis, it is still a one-of-a-kind diagnosis, so it doesn't give me a group to join or that kind of thing. But now I've got that research paper that I've read and read, and asked ChatGPT to verify that I've understood it right in some places, you know, with the faith that we put into ChatGPT (laughs), I've got a better understanding and I've got something now that I can look back on, the things that happened when my daughter was one, 2, 3, 4 and her development was all over the place and people thought that I was slightly crazy for the things I was saying, that “Actually, no, I can see what's happening.” So, it's like the picture's starting to come into focus but there's work to do. I haven't got a timeframe on that, I don't know when it's going to come together. And I always say that I'm a prolific stalker of the postman; ever since our first genetic tests you're just constantly waiting for the letters to drop through the door. So a diagnostic odyssey to me is just waiting for random events. Adam: I think what you've both kind of really clearly elaborated on is how you're the ones that are having to navigate this journey, you're the ones that are trying to piece this puzzle together, and the amount of time you're investing, all whilst navigating and looking after your child and trying to cope with the daily lived experience as well. And something you've both touched on that I'd love to draw out more is about how exactly was the information shared with you about the lack of diagnosis or the VUS or what's going on, because in our case you get this bit of paper through the post that has all these numbers and it's written in clinical speak and we had no conversation with the geneticist or the doctors. You see this bit of paper and you're reading it, scared for what the future will hold for your child, but I'd love to know like how were you communicated whilst all this is going on, how did you actually find out the next steps or any kind of future guidance. Lisa: So I think in our case we kept sort of going onto neuromuscular appointments, and I think for probably the first 5 years of my daughter's life I kind of had this very naïve thought that every time we turned up to an appointment it would be ‘the one' and then…   I think it would've been really helpful actually in those initial stages if they had said to us, “Actually, we don't know when this is going to happen, if it's even going to happen, you need to kind of prepare yourself for that.” It sounds fairly obvious to say but you don't know what you don't know. And in some ways we were getting genetic test results back for some really quite horrible things and they would tell us, “Oh it's good news, this mitochondrial disorder hasn't come up,” and so part of you is like, “Yay!” but then another part of you is thinking, “Well if it's not that what is it?” And we've very much kind of danced around and still don't really have an answer to whether it's life-limiting. We know it's potentially life-threatening and we have certain protocols, but even that is tricky. We live in North Yorkshire, and our local hospital are amazing. Every time we go in, if it's anything gastro-related, they say to me, “What's the protocol from Great Ormond Street?” and I say, “We don't have one” (laughs) and that always causes some fun. We try to stay out of hospitals as much as we absolutely can and do what we can at home but, equally, there's a point where, you know, we have to be guided by where we're going with her, with the path, and lots of phone calls backwards and forwards, and then is it going to be a transfer down to Great Ormond Street to manage it. And actually the way I found out that nothing had been found from 100,000 Genomes was in a passing conversation when we had been transferred down to Great Ormond Street and we'd been an inpatient for about 6 weeks and the geneticist said to me, “So obviously with you not having a diagnosis from the 100,000 Genomes…” and I said, “Sorry?  Sorry, what was that?  You've had the information back?”  And she said, “Well, yes, did nobody write to you?” and I said, “No, and clearly by my shock and surprise.” And she was a bit taken aback by that, but it happened yet again 2 years later (laughs) when she said, “Well you know everything's been reanalysed” and I said, “No.”  (Laughs)  And, so that's very much, it still feels an awful lot like I'm doing the heavy lifting because we're under lots of different teams and even when they're working at the same hospital they don't talk to each other. And I do understand that they're specialists within their own right, but nobody is really looking at my daughter holistically, and there are things that kind of interrelate across.    And at one of the talks I attended this morning they were talking about the importance of quality of life, and I think that is something that has to be so much more focused on because it's hard enough living without a diagnosis, but when you're living with a bunch of symptoms that, I think the best way I can describe it is at the moment we've got the spokes of the umbrella but we don't have the wrapper, and we don't know where we're going with it. We can't answer her questions, we can't even necessarily know that we're using the most effective treatments and therapies for her, and she's frustrated by that now, being 16, in her own right, as well as we are. And I'm panicking about the navigation towards Adult Services as well because at the minute at least we have a clinical lead in our amazing local paediatrician but of course once we hit and move into that we won't even have him and that's a really scary place to be, I think. Adam: Jo, is there anything you wanted to add on that in terms of how you've been communicated to whilst all this is going on? Jo: Yeah, so I think part of what makes it difficult is if you're across different hospitals because they're not necessarily going to see the same information. So obviously it was a bit of a different time when I got our results, but I got our results on a virtual appointment with a neurologist in one hospital, in the tertiary hospital, and because he could see the screen because it was the same hospital as genetics, and he said, “Oh you've got this” and then the letter came through later. When I had my next appointment with the neurologist in our primary hospital, or secondary care, whatever it's called, in that hospital, he hadn't seen that, so I'm telling him the results, which isn't ideal, but it happens quite a lot. What I think is quite significant to me is the reaction to that VUS.  I have to give it, the doctors that look after my daughter are brilliant, and I'm not criticising them in any way but their reaction to a VUS is “I'm so grateful for the persistence to get to a diagnosis.” Neurologists are a bit more like “Oh it's a VUS so it might be significant, it might be nothing.” Actually, as a patient, as in a parent, you actually want to know is it significant or not, “Do I look at it or not?” And, I mean, like I said, there were no research papers to look at before anyway until a few months ago so I didn't have anything to look at, but I didn't want to look at it either because you don't want to send yourself off down a path. But I think that collective sort of idea that once someone gets a VUS we need a pathway for it, “What do we do with it, what expectation do we set the patients up with and what is the pathway for actually researching further?” because this is where we really need the research. Adam:  Thank you, Jo. So, Emma, over to you in terms of how best do you think clinicians can actually support patients at navigating this odyssey and what's the difference between an initial diagnosis and a final diagnosis and how do you then communicate that effectively to the patients and their family?   Emma: So I think a key thing for me, and it's come up just now again, is that you need to remember as a doctor that the things you say at critical times in a patient's or parent's journeys they will remember – they'll remember it word for word even though you won't – and thinking about how to do that in the most sensitive, empathetic, calm, not rushed way is absolutely key.   And there are some difficulties with that when you're in a very high-pressure environment but it is absolutely crucial, that when you are communicating information about test results, when you're talking about doing the test in the first place, you're consenting the family, you're explaining what you're trying to do and those conditions, you balance how much information you give people.    So, you were talking earlier about “So you haven't got this diagnosis, you haven't got that diagnosis,” I often think it's…  We're often testing for numerous different conditions at the same time, I couldn't even list them all to the parents of the children or the patient that I'm testing. It's key to try and provide enough information without overwhelming people with so much information and information on specific conditions you are just thinking about as a potential.  Sometimes very low down your list actually but you can test for them.    Because people go home and they use the internet and they look things up and they get very, very worried about things. So, for me it's trying to provide bite-sized amounts of information, give it the time it deserves, and support people through that journey, tell them honestly what you think the chance of finding a diagnosis is. If you think it's unlikely or you think you know, sharing that information with family is helpful.   Around uncertainty, I find that a particular challenge. So, I think we've moved from a time when we used to, in this country, declare every variant we identified with an uncertain significance. Now, if we remember that we've all got 5 million variants in our genome, we've all got hundreds and hundreds… thousands and thousands, in fact, of variants of uncertain significance in our genetic code. And actually, unless you think a variant of uncertain significance genuinely does have a probability of being the cause of a child's or a patient's condition, sharing that information can be quite harmful to people.    We did a really interesting survey once when we were writing the guidelines for reporting variants of uncertain significance a few years ago. We asked the laboratories about their view of variants of uncertain significance and we asked the clinicians, and the scientists said, “We report variants of uncertain significance because the clinicians want them” and the clinicians said, “If the labs put the variant of uncertain significance on the report it must be important.” And of course, if you're a parent, if the doctor's told you the variant is a variant of uncertain significance of course you think it's important.    So, we should only be sharing that information, in my opinion, if it genuinely does have a high likelihood of being important and there are things that we can do. And taking people through that journey with you, with the degree of likelihood, the additional tests you need to do and explaining to them whether or not you think you will ever clarify that, is really, really key because it's very often that they become the diagnosis for the family.  Did I cover everything you think's important, both of you?  Lisa: I think the one thing I would say is that when you are patient- or parent-facing, the first time that you deliver that news to the parent… you may have delivered that piece of news multiple times and none of us sit there expecting you to kind of be overcome with emotion or anything like that but, in the same way that perhaps you would've had some nerves when, particularly if it was a diagnosis of something that was unpleasant, you know, to hold onto that kind of humanity and humility. Because for those patients and parents hearing that news, that is the only time they're ever hearing that, and the impact of that, and also, they're going on about with their day, you don't know what else they're doing, what they're juggling.    We're not asking you all to be responsible for kind of, you know, parcelling us up and whatnot but the way information is imparted to us is literally that thing we are all hanging our hats on, and when we're in this kind of uncertainty, from my personal experience I'm uncomfortable, I like to be able to plan, I'm a planner, I'm a researcher, I like to sort of look it up to the nth degree and that, and sitting in a place without any of that is, it's quite a difficult place to be. And it's not necessarily good news for those parents when a test comes back negative, because if it's not that then what is it, and that also leaves you feeling floundering and very isolated at times.  Adam: Yeah, and you touched upon the danger of like giving too much information or pushing families down a particular route, and then you have to pull them out of it when it's not that.   You talked about the experience you had, you felt like you'd found your home and then it's like, “Well, no, no, sorry, actually we don't think it's that.” And you've invested all of your time and your emotion into being part of that group and then you're kind of taken away again. So it's to the point where you have to be really sure before you then communicate to the families, and obviously in the meantime the families are like, “We just need to know something, we need to know,” and it's that real fine line, isn't it?    But, Jamie, over to you. Just thinking about the evolving nature of genomic diagnosis, what role does research play in refining or confirming a diagnosis over time?  Jamie: So it's really, really difficult actually to be able to kind of pinpoint one or 2 things that we could do as a community of researchers to help that journey, but perhaps I could reflect on a couple of things that I've seen happen over time which we think will improve things. And one of that's going back to the discussion that we've just had about how we classify genetic variants. And so, behind that kind of variant of uncertain significance there is a huge amount of effort and emotion from a scientist's side as well because I think many of the scientists, if not all, realise what impact that's going to have on the families.   And what we've tried to do as a community is to make sure that we are reproducible, and if you were to have your data analysed in the North West of England versus the South West that actually you'd come out with the same answer. And in order to do that we need guidance, we need recommendations, we need things that assist the scientists to actually classify those variants.  And so, what we have at the moment is a 5 point scale which ranges from benign to likely benign, variant of uncertain significance, unlikely pathogenic variant and pathogenic variant. It's objective as to how we classify a variant into one of those groups and so it's not just a gut feeling from a scientist, it's kind of recordable measurable evidence that they can provide to assist that classification.   So in many instances what that does is provide some uncertainty, as we've just heard, because it falls into that zone of variant of uncertain significance but what that also does is provide a framework in which we can generate more evidence to be able to classify it in one direction or another to become likely pathogenic or to become likely benign. And as a research community we're equipped with that understanding –– and not always with the tools but that's a developing area – to be able to do more about it.   What that doesn't mean is that if we generate that evidence that it can translate back into the clinic, and actually that's perhaps an area that we should discuss more. But kind of just generating that evidence isn't always enough and being able to have those routes to be able to translate back that into the hands of the clinicians, the clinical scientists, etc, is another challenge. Adam:  And how do you think we can drive progress in research to deliver these answers faster, to really try and shorten those diagnostic journeys, like what are the recommendations that you would say there? Jamie:  So being able to use the Genomics England data that's in the National Genomic Reference Library, as well as kind of other resources, has really transformed what we can do as researchers because it enables teams across the UK, across the world to work with data that otherwise they wouldn't be able to work with.   Behind that there's an infrastructure where if researchers find something which they think is of interest that can be reported back, it can be curated and analysed by teams at Genomics England and, where appropriate, kind of transferred to the clinical teams that have referred that family. And so having that pathway is great but there's still more that we can do about this. You know, it's reliant on things going through a very kind of fixed system and making sure that clinicians don't lose contact with families – you know, people move, they move locations, etc. And so, I think a lot of it is logistical and making sure that the right information can get to the right people, but it all falls under this kind of umbrella of being able to translate those research findings, where appropriate, into clinical reporting.   Adam:  Thank you. And, Emma, is there anything you would add in terms of like any key challenges that you think need to be overcome just to try and shorten the journeys as much as possible and find the answers to get a diagnosis?  Emma: I think trying to bridge that gap between some of the new technologies and new approaches that we've got that we can access in a research context and bringing those into diagnostics is a key area to try to reduce that diagnostic odyssey, so I really want to see the NHS continuing to support those sorts of initiatives.   We're very lucky, as Jamie said, the National Genomic Research Library has been fundamental for being able to reduce the diagnostic odyssey for large numbers of patients, not just in this country but around the world, and so trying to kind of look at how we might add additional data into the NGRL, use other research opportunities that we have in a more synergistic way with diagnostics I think is probably key to being able to do that.    We are very lucky in this country with the infrastructure that we've got and the fact that everything is so joined up. We're able to provide different opportunities in genomics for patients with rare conditions that aren't so available elsewhere in the world.  Adam: Great, thank you. I think we're it for time, so thank you very much to the panel. And I'd just say that if you do have any further questions for ourselves as participants then we're only too happy to pick those up. Thank you for lasting with us ‘til the end of the day and hope to see you soon.  -- Sharon: A huge thank you to our panel, Adam Clatworthy, Emma Baple, Jo Wright, Lisa Beaton and Jamie Ellingford, for sharing their insights and experiences. Each year at the summit, the Behind the Genes stage hosts podcast style conversations, bringing together researchers, clinicians and participants to discuss key topics in genomics.  If you're interested in attending a future Genomics England Research Summit, keep an eye out on our socials. If you'd like to hear more conversations like this, please like and subscribe to Behind the Genes on your favourite podcast app. Thank you for listening.    I've been your host, Sharon Jones. The podcast was edited by Bill Griffin at Ventoux Digital and produced by Deanna Barac.

In this conversation, I explore a fascinating paradox in our relationship with artificial intelligence.Why do we demand absolute perfection from AI while accepting human error as inevitable? When an LLM hallucinates or cites fake sources, I get frustrated. But when a colleague misspeaks or misremembers, I give them grace. Why the double standard?I walk through the reality of human error across industries:* Diagnostic mistakes happen in 5-20% of doctor visits* 80% of aviation accidents trace back to human error* 20% of Big Four audits have significant deficiencies* Even elite professionals only achieve 90-95% accuracy.The thread tying all of this together is simple but uncomfortable: our imperfections are what make us human and interesting. AI-generated content feels soulless. You can sense it. It lacks emotion, depth, playfulness, and personality.I believe we're heading toward an age where we'll pay a premium for human-generated content, art, and music. We think we can scale the human experience with AI, but what we'll find instead is an overly perfect, emotionless dark age of art and culture.The choice isn't between perfect AI or imperfect humans. It's about deciding which imperfections we're willing to live with.TIMESTAMPS00:00 Hello from Australia!01:16 We Expect Perfection out of AI and Not in Humans, Why?06:41 The Paradox of Perfection in AI and Humanity07:05 Mentoring Opportunities07:26 The Book of the Week08:34 Grab My Guidebooks08:51 Check this outLinkshttps://www.who.int/news-room/fact-sheets/detail/patient-safetyhttps://www.sciencedirect.com/science/article/pii/S2666691X23000246https://tax.thomsonreuters.com/news/audit-deficiency-rate-drops-in-2024-in-sign-of-improvement/https://www.researchgate.net/publication/1907590_Thinking_is_Bad_Implications_of_Human_Error_Research_for_Spreadsheet_Research_and_PracticeCONNECT WITH MENewsletter: https://www.ninasnotes.xyzLongevity.Technology Unlocked Podcast: https://longevity.technology/unlocked/Longevity Guidebooks: https://ninapatrick.xyz/guidebooksMentoring: https://ninapatrick.xyz/startup-mentor/LinkedIn: https://www.linkedin.com/in/ninapatrick/Website: https://www.ninapatrick.xyz Get full access to Nina's Notes at www.ninasnotes.xyz/subscribe

It's feared there could be widespread procedure cancellations in the MidWest as a key branch of healthcare personnel have threatened industrial action. Clinical Measurement Physiologists represented by Fórsa are set to meet HSE officials at the Workplace Relations Commission today, in a long-running dispute over pay and conditions. CMPs deliver diagnostic services across cardiac, respiratory, neurophysiology, gastrointestinal and vascular care, and Fórsa claims its members will engage in a work-to-rule from Friday if an agreement can't be reached. Fórsa Secretary Linda Kelly claims there's a myriad of issues.

In this episode of "PICU Doc On Call," Drs. Pradip Kamat and Rahul Damania discuss the acute management of a 14-year-old boy with severe rectal bleeding and hypertension, ultimately diagnosed with inflammatory bowel disease (IBD). They review the approach to pediatric lower GI bleeding, diagnostic workup, and imaging, emphasizing early recognition and resuscitation. They outline IBD management, including steroids, biologics such as infliximab, and nutritional support, while highlighting the importance of screening for infections before immunosuppression. The episode provides practical insights for PICU physicians on handling acute GI emergencies in children.Show Nighlights: Clinical case of a 14-year-old male with hypertension and rectal bleeding.Diagnosis of inflammatory bowel disease (IBD) following significant blood loss.Approach to pediatric rectal bleeding and its implications.Diagnostic workup including laboratory tests and imaging modalities.Management strategies for IBD in acute pediatric care.Importance of early recognition and resuscitation in cases of shock.Physiological principles related to blood loss and shock in children.Differential diagnoses for lower gastrointestinal bleeding in pediatrics.Initial evaluation and stabilization protocols for pediatric patients.Nutritional support and multidisciplinary care in managing IBD. References:Romano C, Oliva S, Martellossi S, et al. Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of Pediatric Gastroenterology. World J Gastroenterol. 2017;23(8):1326-1337.Pai AK, Fox VL. Gastrointestinal bleeding and management. Pediatr Clin North Am. 2017;64(3):543-561.Padilla BE, Moses W. Lower gastrointestinal bleeding and intussusception. Surg Clin North Am. 2017;97(1):63-80.Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient management of inflammatory bowel disease-related complications. Clin Gastroenterol Hepatol. 2020;18(11):2417-2428.Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017;1(2):147-158.Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric inflammatory bowel disease. Pediatrics. 2022;150(6):e2022059341.Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-1060.Conrad MA, Rosh JR. Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2017 Jun;64(3):577-591.

Stephen Ross forgot who he hired at his introductory press conference and Pat Leonard sits in and discusses the changes taking place since John Harbaugh has taken over the New York Giants.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Benjamin Tolchin, MD, MS, FAAN, joins the podcast to provide clinical perspective on the recently published American Academy of Neurology (AAN) guidelines on functional seizures, drawing on his role as a contributing author to the recommendations. Tolchin, Director of the Center for Clinical Ethics at Yale New Haven Health and Associate Professor of Neurology at Yale School of Medicine, discusses what prompted the development of the first AAN guideline in this space and how the evidence base evolved to support formal recommendations. The conversation explores key considerations around diagnosing functional seizures, including history, semiology, EEG use, and the growing role of video documentation. Tolchin also addresses how clinicians should approach psychiatric comorbidities and co-occurring epilepsy, the evidence supporting psychological interventions, why pharmacologic therapies are not recommended for functional seizures themselves, and where major gaps remain in research to advance care in the years ahead.Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.Episode Breakdown: 1:10 – Why growing evidence prompted the first AAN guideline on functional seizures 3:20 – Diagnostic priorities including history, semiology, EEG, and video documentation 6:15 – Assessing psychiatric comorbidities and co-occurring epilepsy in functional seizures 9:15 – Neurology News Minute 11:30 – Evidence supporting psychotherapy for functional seizures 14:50 – Pharmacological evidence and use of antiseizure medications for functional seizures 18:35 – Barriers to advancing clinical trials in functional seizures 22:05 – Research priorities to refine treatment and long-term outcomes The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

203. The Human Element in Leadership (with Helen Honisett)   In this episode of the Visibility Factor podcast, host Sue Barber speaks with Helen Honisett, CEO of Defy Expectations, about her unique approach to leadership. They discuss the importance of clarity in leadership, the impact of generational differences, and the concept of 'love leadership' which emphasizes human connection and care. Helen shares insights on the use of diagnostic tools for leadership development and the role of AI in enhancing leadership effectiveness. The conversation highlights the need for strategic thinking in leadership and the importance of understanding one's value in the evolving workplace. Takeaways Helen emphasizes the importance of clarity in leadership. Great leadership impacts personal wellbeing and professional development. Generational differences can enhance workplace dynamics. Love leadership focuses on human connection and care. Diagnostic tools can identify leadership strengths and weaknesses. AI should enhance human leadership, not replace it. Strategic thinking is crucial for effective leadership. Organizations need to invest wisely in leadership development. Cultural ROI is as important as financial ROI in leadership. Understanding one's value is key in the age of AI.   The book that Helen recommends is Letting Go by David R. Hawkins   Helen's website: https://www.defyexpectations.co.uk/ LinkedIn: https://www.linkedin.com/in/hhonisett/   Link to Order Your Journey to Visibility Workbook   Thank you for listening to The Visibility Factor Podcast!    Check out my website to order my book and view the  videos/resources for The Visibility Factor book and Your Journey to Visibility Workbook. As always, I encourage you to reach out! You can email me at hello@susanmbarber.com. You can also find me on social media everywhere –Facebook, LinkedIn, and of course on The Visibility Factor Podcast! I look forward to connecting with you!       If you liked The Visibility Factor Podcast, I would be so grateful if you could subscribe and leave a review wherever you listen to podcasts! It helps the podcast get in front of more people who can learn how to be visible too!       

Le cancer touche de plus en plus de personnes, de plus en plus jeunes. Pourtant, il est difficile de trouver des informations fiables, simples à comprendre, sur le sujet. C'est quoi le cancer ? Qu'est-ce qui peut le prévenir, et au contraire, le causer ? Comment guérir ? Pour faire le point sur toutes les questions que l'on peut se poser, je reçois le professeur Fabrice Barlesi, oncologue et Directeur Général de l'Institut Gustave Roussy, le principal centre de recherche, de diagnostic et de traitement sur le cancer.Le livre du Professeur Barlesi : https://www.editions-privat.com/nos-livres/sport-et-sante/guerir-le-cancer-commence-aujourdhuiMon site : https://www.fabricemidal.comFacebook Fabrice Midal : https://www.facebook.com/FabriceMidalFacebook du podcast Dialogues : https://www.facebook.com/dialogues.fmInstagram Fabrice Midal : https://www.instagram.com/fabricemidalInstagram du podcast Dialogues : https://www.instagram.com/fabricemidal_dialogues/Tiktok : https://www.tiktok.com/@fabricemidalMes trois chaînes YouTube :Mes vidéos : https://www.youtube.com/@fabricemidal1Les Dialogues : https://www.youtube.com/@dialoguesfmLes méditations guidées : https://www.youtube.com/@mediteravecfabricemidalMes podcasts :Le podcast de Fabrice Midal (toutes mes vidéos en version audio) :

Experience is your greatest asset—until it creates your biggest blind spot. In the Season 2 premiere of Windshield Time, Chris Elmore and Matthew Barbosa dismantle the myth that "seasoned pros don't need checklists." If you're relying on your gut to diagnose, you're leaving money, trust, and your reputation on the table. We dive into why the diagnostic checklist isn't about finding the problem—it's about the "Juggernaut Strike": making one undeniable point that secures the sale before you even open your mouth. In this episode, you'll learn: The Routine Trap: How your "automatic" expertise creates invisible blind spots. Troubleshooting vs. Diagnosing: Why finding the fix is only 10% of the job. The "Greens" Strategy: How documenting what isn't broken builds more trust than finding what is. Translation Over Technicality: Using the checklist as a shared language with the customer. The Documentation Premium: Why knowledge has zero value until it's shared with the person paying the bill.

Cette semaine Alexia vous raconte l'histoire de Wendy qui a fait face lors de sa grossesse à un diagnostic de trisomie. Des personnes m'ont partagé leur témoignage, leur combat, leur miracle. J'ai choisi de les réunir sur ce podcast et de vous les raconter. Ces histoires vous montreront qu'avec Dieu, il y a toujours une raison d'y croire.Si vous aussi vous avez une histoire à partager n'hésitez pas à envoyer un e-mail à alexiavousraconte@gmail.com ou un DM sur ma page instagram ⁠⁠⁠⁠@alexiavousraconte⁠⁠ ⁠⁠N'hésitez pas à me suivre sur Instagram : ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠alexiavousraconte⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TAGS : Podcast chrétien, histoire, Bible, témoignage, histoire vraie, Jésus, encouragement, foi, enseignement, message biblique, Dieu, miracle, versets, storytime

Welcome to Episode 52 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! NSAIDs National Institutes of Health. (2022). Nonsteroidal antiinflammatory drugs. LiverTox: Clinical and research information on drug-induced liver injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548614/ LFTs / Drug-Induced Liver Injury American Association for the Study of Liver Diseases. (2023). Practice guidance on drug, herbal, and dietary supplement–induced liver injury. Hepatology. Retrieved from https://journals.lww.com/hep/fulltext/2023/03000/aasldpracticeguidanceondrug,herbal,and.28.aspx Toxicology Screening StatPearls Publishing. (2023). Toxicology screening. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK499901/ Academy of Diagnostic & Laboratory Medicine. (2023). Testing for drugs of misuse to support the emergency department. Retrieved from https://myadlm.org/science-and-research/academy-guidance/testing-for-drugs-of-misuse-to-support-the-emergency-department CT Utilization / Imaging American College of Emergency Physicians. (2022). The renewed necessity of robust clinical judgment in CT scan utilization. ACEP Now. Retrieved from https://www.acepnow.com/article/the-renewed-necessity-of-robust-clinical-judgment-in-ct-scan-utilization/ Appropriate Testing / Overuse Context Melnick, E. R., et al. (2023). GRACE-2: Guidelines for reasonable and appropriate care in the emergency department. Academic Emergency Medicine. Retrieved from https://onlinelibrary.wiley.com/doi/10.1111/acem.14495 More from us: Our CME courses: EM Boot Camp: https://courses.ccme.org/course/embootcamp/about EM Boot Camp Pharmacology Workshop: https://bit.ly/2I44xld Bouncebacks! Medical & Legal: https://courses.ccme.org/education/bouncebacks-medical-and-legal Mastering Emergency Imaging: https://courses.ccme.org/education/mastering-emergency-imaging Advanced EM Boot Camp: https://courses.ccme.org/course/advancedbootcamp/about Advanced ECG Workshop: https://bit.ly/aembc-ecg Advanced Imaging Workshop: https://bit.ly/aembc-imaging EM & Acute Care: https://courses.ccme.org/course/ema/about National EM Board Review: https://courses.ccme.org/course/nembr/about High Risk Emergency Medicine: https://courses.ccme.org/course/hrem The Heart Course: https://courses.ccme.org/course/theheartcourse The Cadaver-Based Procedures & Suturing Courses: https://courses.ccme.org/course/cadaver EM:Prep LLSA Review: https://courses.ccme.org/course/em-prep/about EMCert Module Mastery: https://courses.ccme.org/course/emcertmodule USC Trauma Course: https://courses.ccme.org/course/usc-trauma ACOEP Scientific Assembly: https://courses.ccme.org/course/acoep Mastering Acute Care Charting - 2023 Updates: https://courses.ccme.org/course/macc Flourishing in Medicine: https://courses.ccme.org/course/flourishing-in-medicine The DEA Licensee SUD Training Course: https://courses.ccme.org/course/dea ACOFP On-Demand: https://courses.ccme.org/education/acofp25-clinical-selects The Airway and Lung Course: https://courses.ccme.org/education/airway Mastering Pediatric Emergencies: https://courses.ccme.org/course/pediatric-em Innovations in ED Management: https://courses.ccme.org/course/innovationsined American Osteopathic Association Courses: https://aoa.coursehost.net EM Cases Summit: https://courses.ccme.org/education/em-cases-summit-2024 IncrEMentuM Conference – On-Demand: https://courses.ccme.org/education/incrementum-2025 Our social media: TikTok: https://www.tiktok.com/@ccmecourses Instagram: https://www.instagram.com/ccmecourses Facebook: https://www.facebook.com/CenterForMedicalEducation LinkedIn: https://www.linkedin.com/in/rickbukata Our podcasts: The 2 View Podcast (Free): Subscribe on Apple Podcasts https://apple.co/3rhVNZw​ Subscribe on Google Podcasts: http://bit.ly/2MrAHcD​ Subscribe On Spotify: http://spoti.fi/3tDM4im Risk Management Monthly Podcast (Paid CME): https://www.ccme.org/riskmgmt ** The information in this video is not intended nor implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained in this video is for general information purposes only and does not replace a consultation with your own doctor/health professional. The information in this video is for informational purposes only and not for the purpose of providing legal advice. You should contact your attorney to obtain advice with respect to any particular issue or problem. Nothing here should be construed to form an attorney-client relationship. ** emergencymedicine #cme

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Joshua: Resilience.Millions of families with children suffering from rare diseases endure years of frustration and uncertainty, seeking answers from specialists who rarely collaborate. Joshua Resnikoff, CEO and Cofounder of Sunstone Health, has been there. His middle child's years-long fight for a diagnosis inspired him to tackle this systemic inefficiency with AI-powered innovation.Sunstone Health uses AI to analyze healthcare claims data, identifying children who may have genetic conditions, like pediatric epilepsy or autism, and accelerating their path to diagnosis and care. “On average right now, it takes seven years for a family to go from first symptom to a care path that works for them,” Joshua explained in today's episode. “We can take that seven-year process and condense it down into 12 weeks.”This groundbreaking approach provides a win-win solution for families and health plans alike. By identifying patterns in data, Sunstone Health not only helps families avoid the “diagnostic odyssey” of endless referrals but also reduces healthcare costs. “Ultimately, we are saving the plans, the insurance, the employers—whoever is the financial backstop for that family—a lot of money,” Joshua said.The company's innovative model charges health plans only when results are delivered, making it a no-risk decision for employers looking to improve care while managing costs. Sunstone Health has already touched the lives of nearly half a million people through partnerships with health plans, scaling rapidly since its pilot phase.In addition to changing lives, Sunstone Health is raising capital via regulation crowdfunding on Wefunder. This community round allows families and supporters to invest in the company's vision alongside professional investors. “We opened up a few hundred thousand dollars so families could join our mission,” Joshua shared. The campaign has been so successful that Sunstone Health has reopened the round to accommodate more investors.This episode highlights the power of technology and mission-driven innovation to solve seemingly intractable problems. With AI and dedication, Joshua and his team are transforming the lives of families navigating the challenges of rare diseases.tl;dr:Joshua shared how his personal experience inspired Sunstone Health's AI-powered diagnostic solution for rare diseases.Sunstone Health condenses the average 7-year diagnostic process into just 12 weeks for families.The innovative model benefits families and health plans by aligning financial incentives with better care.Sunstone Health is raising capital through regulation crowdfunding, welcoming families and investors to join its mission.Joshua's resilience, driven by optimism and grit, has been key to Sunstone's success and growth.How to Develop Resilience As a SuperpowerJoshua identified resilience—what he calls “grit”—as his defining superpower. He explained, “To do something like this, it just takes a lot of resilience and determination.” Building a company to tackle the systemic inefficiencies in healthcare required overcoming countless challenges. From skeptics who dismissed the problem as “too big to solve” to navigating obstacles in scaling Sunstone Health, Joshua's perseverance has been key. He shared, “There are going to be such deeply dark and frustrating times as a founder…you just have to stay optimistic.”Joshua's resilience was evident early in life when he taught himself to code in BASIC as a child, spending hours figuring out how to make things work. Later, while working full-time as a biomedical engineer at Harvard, he co-founded a company that unexpectedly went viral, selling eco-friendly travel mugs featured on Oprah's blog and in the New York Times. Despite juggling two demanding roles, he stayed determined and made both endeavors successful.Tips for Developing Resilience:Stay Optimistic: Focus on opportunities rather than obstacles, even in challenging situations.Pursue What You Love: Work on projects that deeply resonate with you to sustain motivation through tough times.Embrace Determination: Commit to pushing through difficulties with persistence and grit.Learn from Challenges: View setbacks as opportunities to grow and improve.By following Joshua's example and advice, you can make resilience a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileJoshua Resnikoff (he/him):CEO and Cofounder, Sunstone HealthAbout Sunstone Health: Sunstone Health is an AI-powered precision health platform designed to help families and health plans recognize developmental delay earlier—before uncertainty turns into years of fragmented care and unnecessary cost. By analyzing health system data to identify early patterns of developmental complexity, Sunstone helps guide children toward clearer next steps while supporting families through what is often a long and confusing journey. The result is earlier clarity for families, more coordinated care for clinicians, and meaningful cost reduction for employers—without disrupting existing care or asking families to wait when the signs are already there.Website: sunstonehealth.comCompany Facebook Page: facebook.com/SunstoneHealthOfficialCompany Twitter Handle: @Sunstone_HealthOther URL: wefunder.com/sunstone.healthBiographical Information: Biomedical engineer and entrepreneur in translational science and consumer products. 14 patents, work showcased in national news, and has scaled businesses to >3000x ROI. Focused on using business as a force for good.LinkedIn Profile: linkedin.com/in/joshuaresnikoffSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.SuperCrowdHour, January 21, 2026, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “From $10 to Impact: How Anyone Can Become an Impact Investor.” Drawing on his experience as an investment banker, impact investor, and community-building leader, Devin will explain how everyday people can start investing small amounts to support mission-driven companies while pursuing financial returns. In this session, he'll break down the basics of regulated investment crowdfunding, show how impact and profit can align, and share practical steps for identifying opportunities that create real-world change. As an added benefit, attendees can become an Impact Member of the SuperCrowd for just $4.58 per month to receive an exclusive private Zoom meeting invitation with Devin, free tickets to paid SuperCrowd events, and the opportunity to directly support social entrepreneurs, community builders, and underrepresented founders.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year. Learn more about sponsoring the event here. Interested in speaking? Apply here. Support our work with a tax-deductible donation here.Demo Day at SuperGreen Live. Apply now to present at the SuperGreen Live Demo Day session on January 22! The application window is closing soon; apply today at 4sc.fun/sgdemo. The Demo Day session is open to innovators in the field of climate solutions and sustainability who are NOT currently raising under Regulation Crowdfunding.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on January 27th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Join C-AR Annual Reporting: Requirements, Deadlines, and Lessons Learned from the Field on January 14, 2026, an informative online webinar designed to help crowdfunding issuers and professionals clearly understand C-AR annual reporting requirements, key deadlines, and real-world insights to stay compliant and prepared.Join UGLY TALK: Women Tech Founders in San Francisco on January 29, 2026, an energizing in-person gathering of 100 women founders focused on funding strategies and discovering SuperCrowd as a powerful alternative for raising capital.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Welcome to Resiliency Radio with Dr. Jill Carnahan, where today's episode explores how to heal from within by optimizing gut hormones, peptides, and recovery biology. Dr. Jill is joined by Dr. Daniel Chille, integrative and functional medicine expert and founder of TBD Fit, to break down the science of recovery, performance, and long-term health—from elite athletes to everyday high performers.

The Centers for Medicare and Medicaid Services has finalized the 2026 Outpatient Perspective Payment System (OPPS) rule, with most policies taking effect on January 1, 2026. Jenna Stern, Vice President of Regulatory Affairs and Public Policy at Vizient, joins host Carolyn Liptak, Pharmacy Executive Director in Vizient's Center for Pharmacy Practice Excellence, to discuss key updates to payment policies, payment rates, and quality provisions affecting Medicare beneficiaries receiving care in hospital outpatient departments and ambulatory surgical centers.   Guest speaker:    Jenna Stern Vice President of Regulatory Affairs and Public Policy Vizient Host:   Carolyn Liptak, MBA, RPh  Pharmacy Executive Director Vizient  Verified Rx Host   Show Notes: 00:05 — Introduction Announcer welcomes listeners to VerifiedRx. Host Carolyn Liptak, Pharmacy Executive Director at Vizient, introduces the episode focus: the 2026 CMS Outpatient Prospective Payment System (OPPS) Final Rule. Guest: Jenna Stern, VP of Regulatory Affairs and Public Policy at Vizient.   01:12 — Overview of the OPPS Final Rule OPPS sets Medicare payment for most hospital outpatient services. Published annually (typically November), effective January 1. Covers payment rates, policies, quality programs, and compliance requirements. Note: CMS delayed enforcement of hospital price transparency requirements until April 1, 2026.   01:34 — Key Takeaways From the 2026 Final Rule Jenna's high-level insights: Hospitals will continue facing financial pressure in 2026. Modest payment rate increase combined with reimbursement-reducing policies. Expansion of site-neutral payment policies will be particularly impactful. Rule reflects emerging administration priorities shaping future policy.   02:21 — OPPS Payment Rate Update for 2026 CMS finalized a 2.6% OPPS schedule increase factor for hospitals meeting quality reporting requirements.   02:40 — What the 2.6% Increase means Based on: 3% market basket update –0.7% productivity adjustment Results in a modest net increase. Slightly better than the proposed 2.4% increase, though still viewed as inadequate. CMS estimates $8 billion increase in total OPPS payments compared to 2025.   03:37 — 340B Remedy Offset: Background From 2018–2022, CMS paid for 340B drugs at ASP –22.5%. Prior Supreme Court decision from 2022 found that CMS lacked authority to vary rates as finalized in prior rulemaking (e.g., without using drug acquisition cost surveys to inform policy).   04:13 — 340B Remedy Offset in the 2026 Final Rule CMS considered increasing the remedy offset from 0.5% to 2%. Stakeholders strongly opposed the increase due to hospital financial strain.   05:10 — Final Outcome CMS retained the 0.5% offset for 2026. CMS signaled that larger offsets may be proposed for 2027. This marks the first year the remedy offset takes effect,   06:00 — Site-Neutral Payment Policy: What It Is Concept: same service = same payment, regardless of site of care. Hospital concern: policy reduces hospital reimbursement without accounting for site of care differences, patient acuity, overhead, or service complexity.   06:15 — Site-Neutral Expansion in the 2026 Rule CMS expanded site-neutral payment to include drug administration services at excepted off-campus provider-based departments.   07:08 — Financial Impact Reimbursement aligns with Physician Fee Schedule rates. CMS estimates $290 million reduction in outpatient spending for 2026. $220 million of savings accrue directly to Medicare. Not implemented in a budget-neutral manner.   08:14 — Non-Opioid Pain Management Payments Temporary additional payments began January 1, 2025. Authorized under the NO PAIN Act (Consolidated Appropriations Act of 2023).   08:28 — What's New for 2026 CMS finalized the renewal of: 5 drugs 13 medical devices eligible for separate payment in HOPD and ASC settings. Per statue, payments available through December 31, 2027.   09:32 — Process Improvements CMS will allow more frequent consideration of new qualifying products (not limited to annual updates). Quality criteria unchanged; timing flexibility added. CMS released guidance on how stakeholders can engage for inclusion.   10:58 — OPPS Drug Acquisition Cost Survey CMS finalized plans to survey hospitals on acquisition costs for separately payable OPPS drugs.   11:21 — Why CMS Is Advancing the Survey Addresses Supreme Court requirements from prior 340B litigation. Aligns with White House Executive Order on lowering drug prices. Positions CMS to use survey data for 2027 rulemaking.   12:47 — OPPS Packaging Thresholds for 2026 Drugs and biologics: Threshold remains at $140. Diagnostic radiopharmaceuticals: Increased to $655 (from $630). Products below thresholds retain Status Indicator “N” (packaged payment).   13:26 — Why Billing Packaged Drugs Still Matters Even though not separately payable, hospitals must bill for packaged drugs. Billing data feeds cost reports used to calculate future bundled payments. Failure to bill can result in inaccurately low reimbursement.   14:14 — Elimination of the Inpatient-Only (IPO) List CMS finalized a three-year transition to eliminate the IPO list by January 1, 2029.   14:32 — Why This Change Is Significant IPO list historically ensured certain services were provided inpatient only. CMS emphasizes provider judgment in determining site of care. Raises concerns about: Patient safety Payer coverage changes Pressure to move services outpatient   16:28 — ASC Covered Procedure List Expansion CMS expanded the ASC Covered Procedure List. Enables more Medicare covered services to be performed in the ASC settings.   16:48 — Price Transparency: Still a Priority No major overhaul, but continued refinement. CMS exploring new uses of price transparency data beyond patient comparison.   17:46 — Most Critical Policies to Watch Jenna highlights: Modest OPPS payment increase Site-neutral payment expansion 340B remedy offset Drug acquisition cost survey Broader regulatory activity beyond OPPS   18:43 — Available Vizient Resources OPPS Final Rule Summary Government Relations & Public Policy Summaries  Advocacy   19:20 — Closing Carolyn thanks Jenna for her insights. Reminder to subscribe, like, and share feedback. VerifiedRx is produced by the Vizient Center for Pharmacy Practice Excellence.   Links | Resources:  Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Rating; Hospital Price Transparency; and Notice of Closure of a Teaching Hospital and Opportunity To Apply for Available Slots: Click Here CMS fact sheet on the Final Rule: Click Here Outpatient Prospective Payment System (OPPS) Drug Acquisition Cost Survey: Click Here Vizient Office of Public Policy and Government Relations final rule summary:  Click Here Final List of Qualifying Products for Separate Payment for non-opioid pain medications: (Table 136, pgs. 1138-1140)   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed    

This episode of TriloTalk explores companion diagnostics and what makes them medical devices. Join Julia Forjanic Klapproth, Senior Partner at Trilogy, Laura Collada, Senior Medical Writing Manager at Trilogy, and Raquel Billiones, Director of Medical Writing at AstraZeneca and learn how in vitro diagnostic tools help pair the right treatment with the right patient and why we can't just test drugs and their companion devices all in one go. Tune in!

Are you missing indolent systemic mastocytosis (ISM)? Learn key clues and best practices in our expert-led program. Credit available for this activity expires: 1/05/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-centered-approaches-indolent-systemic-mastocytosis-2025a100106v?ecd=bdc_podcast_libsyn_mscpedu

enfinnnn 24 podmas complete !!! ahahah

Get a first look at Antech's VMX 2026 education program — built around the realities of clinical practice and the growing need to apply contextualized diagnostics . Join Dr. Michelle Evason (BSc, DVM, DACVIM, MRCVS), Director of Education & Outreach at Antech, and Tammi Lesser, LVT, Regional President, Mars Science & Diagnostics, North America for a behind-the-scenes preview of this year's key themes, including preventive care, case-based learning, and what's new in diagnostic innovation. You'll hear how topics like GI parasite testing, vector-borne disease, and imaging are being brought to life through practical case examples. Plus, gain insight into how veterinary teams can better connect diagnostics to decision-making, communication, and everyday workflow. Tails from the Lab is a production of Antech Diagnostics. The intent of this podcast is to provide education and guidance with the understanding that any diagnostic testing and treatment decisions are ultimately at the discretion of the attending veterinarian within the established veterinarian-patient-client relationship.Just a quick note before we jump into today's episode. Our guests today are Tammi Lesser and Michelle Evason who are employed by Antech. We're sharing this so you have full transparency about the relationships involved.

We discuss a structured, step-by-step guide for conducting a Human Error Diagnostic Study, explaining how to define the problem and scope, gather operational and procedural evidence, quantify and classify errors, and validate findings through observations and interviews with the people performing the work. It emphasizes identifying systemic and human-factors contributors—such as task complexity, cognitive load, weak procedures, and workload conditions—rather than defaulting to retraining as a solution. The guide also outlines how to build a risk profile using frequency, impact, and trends, and how to translate findings into practical, prioritized corrective actions that reduce cognitive and system burden through task redesign, simplification, standardization, and targeted controls. Finally, it recommends defining success metrics and producing clear deliverables, including a findings report, heat maps, root-cause analysis, and an actionable improvement roadmap.To learn more, visit:https://humanerrorsolutions.com/Listen to more episodes on Mission Matters:https://missionmatters.com/author/ginette-collazo/

Sign up for my free class REJECTION SENSITIVITY 101 here!In this episode, I'm breaking down five research-backed facts about ADHD that should fundamentally change how we think about diagnosis, medication, and long-term care. These aren't hot takes. They're uncomfortable truths.Here's what we're covering:• 80% of people stop ADHD medication within the first year—not because it “didn't work,” but because the system failed them• Diagnostic criteria are still wildly outdated, especially for adults, women, and older adults• Many people seek diagnosis because someone else pushes them to, which makes staying in treatment much harder• The “antibiotic fantasy” of ADHD treatment—why trying meds once and quitting is almost guaranteed to fail• Too many clinicians treating ADHD aren't properly trained, creating shame, confusion, and poor outcomesThis episode is about naming what's broken—so you can advocate for better care, better information, and better support.If you have ADHD, love someone who does, or work with ADHD clients or patients… this is required listening.Watch this episode on YouTubeWant help with your ADHD? Join FOCUSED!Have questions for Kristen? Call 1.833.281.2343Hang out with Kristen on Instagram and TikTokSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of HVAC R&D, Ramblin Rhyno' (Rhydon Atzenhoffer) sits down with Greggory Butler, the creator of TA‑14 — a bold, structured approach to residential HVAC diagnostics built not just to teach the steps, but to reset the mindset. A former Army infantryman turned one-man $2M/year service tech, Gregg doesn't shy away from asking tough questions about how we think, troubleshoot, and train in this trade. And in this conversation, we follow suit — with a deep dive into the why behind his method and the real-life impact it's having on techs across the country. But this episode goes beyond diagnostics. It's about challenging the norms that keep the HVAC industry stagnant — and having honest conversations that push us all forward. If you followed Gregg and Rhydon's the recent dialogue on LinkedIn about the role of podcasting, education, and trust in the trades, this episode is what sparked much of their continuation of that conversation — not with outrage, but with open minds. Whether you're a seasoned tech, an industry educator, or just someone who wants to get better at your craft, Gregg brings a clear and powerful voice, a focused mission, and a refreshing lack of fluff.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers Types of SubstancesHosts: Sara Abrahamson, Shaoyuan Wang and Kate Braithwaite.Audio Editing: Kate BraithwaiteReferences:American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, text revision (DSM-5-TR). 5th ed. Washington, D.C.: American Psychiatric Association Publishing; 2022.CAMH. (2013). Inhalants. Inhalants | CAMHCAMH. (2010). Cocaine and Crack. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/cocaineCAMH. (2012). Amphetamines. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/amphetamines#:~:text=Chronic%20use%20of%20amphetamines%20can,can%20also%20cause%20amphetamine%20psychosis.Chae J, Marsden J and Sutherland A. (2024, August 21). Benzodiazepine Withdrawal. Emergency Care BC. Benzodiazepine Withdrawal : Emergency Care BCChildHealthBC. (2023, September 21). Common Street names for Substances. https://childhealthbc.ca/mhsu/common_streetnames_substances/printfileJauch EC. (2023, January 18) Inhalants Clinical Presentation. Medscape. Inhalants Clinical Presentation: History, Physical, CausesKaye, AD, Staser, AN, Mccollins, TS, Zheng, J, Berry, FA, Burroughs, CR, Heisler, M, Mouhaffel, A, Ahmadzadeh, S, Kaye, AM, Shekoohi, S, & Varrassi, G. (2024). Delirium Tremens: A Review of Clinical Studies. Cureus, 16(4), e57601. https://doi.org/10.7759/cureus.57601Long N. (2020, November 3). GHB toxicity. Life in the Fast Lane. GHB toxicity • LITFL • Toxicology Library ToxicantMedx. (2025, November 26). Understanding What is the MOA of Alcohol: A Pharmacological Perspective. What is the MOA of Alcohol? Explained: Receptors and EffectsMendelson, J. H., & Mello, N. K. (1996). Management of cocaine abuse and dependence. The New England journal of medicine, 334(15), 965–972. https://doi.org/10.1056/NEJM199604113341507Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb;101(2):131-81. doi: 10.1016/j.pharmthera.2003.11.002.Nickson C. (2024, December 18). Sedative toxidrome. Life in the Fast Lane. Sedative Toxidrome • LITFL • CCC ToxicologyPorter RS, Kaplan JL, Homeier BP, editors. The Merck manual of diagnosis and therapy. 20th ed. Kenilworth (NJ): Merck Sharp & Dohme; 2018.PsychDB. (2021, March). Opioid Intoxication. Opioid Intoxication - PsychDBPsychDB. (2023, October). Opioid Withdrawal. Opioid Withdrawal - PsychDBPsychDB. (2023 February). Cannabis Withdrawal. Cannabis Withdrawal - PsychDBRoth BL, Gumpper RH. Psychedelics as Transformative Therapeutics. Am J Psychiatry. 2023 May 1;180(5):317-20.Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 Sep;11(9):642-51. doi: 10.1038/nrn2884.

Program notes:0:40 Saturated fat and CVD1:40 When it was reduced in diet only helped in those with high risk2:40 Obesity, diabetes and metabolic syndrome also important3:30 Diagnostic follow up after lung CT4:30 Less intensive than recommended in non-Hispanic blacks5:31 Herpes antiviral and Alzheimer's6:30 Followed for five years7:30 80-90% of population exposed8:30 Change screening criteria for lung ca9:33 Population based study10:30 Calculating pack years11:20 Rolling out through national organizations12:17 End

In this comprehensive training session from the symposium, Tony Gonzalez, Training Director at Fieldpiece, delivers an engaging and practical guide to combustion analysis for HVAC technicians. With 25 years of experience at Fieldpiece—from warehouse worker to training director—Tony brings both technical expertise and real-world application to this 50-minute interactive session focused on the company's CAT 85 combustion analyzer. Tony emphasizes that combustion analysis serves four critical purposes: safety, efficiency, equipment specification verification, and liability protection. He makes a compelling business case for investing in combustion analyzers, noting that preventing just two callbacks or one liability lawsuit can pay for the equipment ten times over. The training walks attendees through the complete process, from properly warming up the analyzer in fresh air (allowing sensors to calibrate to ambient oxygen and zero carbon monoxide) to generating professional PDF reports that can be shared with customers or integrated into work order management systems like ServiceTitan. The session provides detailed guidance on interpreting key measurements, including stack temperature, oxygen percentage, carbon monoxide levels, and draft pressure. Using design parameters from the National Comfort Institute, Tony demonstrates how to diagnose issues by comparing actual readings against acceptable ranges for different furnace types (atmospheric, 80% induced fan, and 90+ percent condensing). He walks through practical troubleshooting scenarios, showing how measurements like high oxygen combined with low stack temperature can point to specific problems like low gas pressure that technicians can then verify and correct. Throughout the presentation, Tony emphasizes proper technique and best practices, from creating test ports at least 12 inches above the inducer fan to the importance of plugging test ports after completion. He also highlights innovative features of Fieldpiece's analyzers, including the hydro cycle pump that eliminates traditional water traps, sensor vault technology that extends sensor life to four years, and built-in wireless connectivity allowing technicians to view measurements on their mobile devices through the Job Link app. Topics Covered: Why perform combustion analysis: Safety verification, efficiency optimization, OEM specification compliance, and liability protection Business benefits: Reducing callbacks, improving OEM relationships, enhancing professional image, and protecting against lawsuits Proper startup procedure: Warming up analyzers in fresh air for accurate oxygen and CO sensor calibration Ambient CO testing: Using combustion analyzers vs. dedicated walk-around detectors for carbon monoxide detection in living spaces Test port installation: Proper placement at least 12 inches above inducer fans and away from 90-degree elbows Key measurements explained: Stack temperature, oxygen percentage, CO PPM, CO air-free, draft pressure, and efficiency calculations Equipment type selection: Choosing correct settings for atmospheric, 80% induced fan, or 90+ percent condensing furnaces Diagnostic interpretation: Using National Comfort Institute parameters to identify issues like excess combustion air or low gas pressure Advanced features: Built-in dual port manometer for gas and static pressure, wireless Job Link app connectivity, and hydro cycle pump technology Report generation: Creating professional PDF reports with company branding for customer documentation and CYA protection Maintenance tips: Checking particle filters, understanding sensor vault technology, and the importance of annual calibration Sensor longevity: Four-year sensor life warranty and field-replaceable sensors without sending equipment for service   Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android.

When growth stalls, it's time to get personal.  Ever felt like you've done all the "right" things in your business, but your results don't add up? You're not alone. In this episode of Your Passion, Purpose, and Personal Brand, host Lisa McGuire sits down with business strategist Maeve Ferguson to challenge everything we've been told about marketing funnels, freebies, and formulas. They explore the quiet revolution happening behind the scenes that few people know about yet. It's one driven by data, dignity, and diagnostics. This is not another pep talk. This is a call to alignment. You'll learn why personalization is the new currency in business, how traditional funnels are quietly failing, and what it really takes to attract high-level clients without selling your soul (or your calendar) to outdated discovery calls. Maeve reveals how entrepreneurs are collapsing months of guesswork into clarity by transforming their intellectual property into score-based diagnostics that do more than convert. They connect. If you've ever whispered to yourself, "I know I'm meant for more...but I don't know where I lost the map," this conversation is your compass. KEY TAKEAWAYS Traditional funnels are outdated. Today's audiences crave personalization. Diagnostic assessments segment leads for higher precision and conversions. Mass emails and checklist freebies often repel rather than attract. Your audience's sophistication has evolved. It's time your strategy does too. Diagnostics let you identify who's truly ready and willing to buy. Rich niche positioning attracts elevated clients and filters out misaligned ones. Mapping your IP (yes, you have it) gives clarity, confidence, and authority. AI and mediocrity are flooding the market. Your differentiation is being real. When you stop chasing and start aligning, sales become symphonic. Success is not about "doing more." It's about becoming more of who you are.   CONNECT WITH MAEVE LinkedIn Profile: https://www.linkedin.com/in/maeveferguson/ Instagram Profile: https://www.instagram.com/iammaeveferguson/ Website: www.maeveferguson.com  CHECK OUT MAEVE'S FREE RESOURCE: https://www.impactscoreassessment.com   CONNECT WITH LISA Beyond the Transaction Mastermind -  Apply to join the group: https://beyondthetransactionmm.com/register Sign up for Lisa's "so much more" newsletter: https://www.thediyframework.com/so-much-more-subscribe  Freedom Reset: Your Next Steps to Realignment  Register: https://go.lisamcguire.com/freedom-reset  Human Design Masterclass Waitlist: https://go.lisamcguire.com/human-design-masterclass-waitlist  Ideal Client Workshop Waitlist: https://go.lisamcguire.com/ideal-client-workshop-waitlist-icww785155  Get your free Human Design Bodygraph: https://lisamcguire.com/get-your-free-chart/   

When you're running a small fleet, a single breakdown can crush your margins and throw your week off track. In this episode of The Long Haul, we sit down with Tyler Robertson, founder and CEO of Diesel Laptops, to talk about why every small carrier needs diagnostic tools in their own hands—not locked behind a shop's schedule or inflated repair fees. We dig into: What makes Diesel Laptops different from other diagnostic tools How owner-ops and small fleets can cut downtime, negotiate smarter, and stay in control Real-world examples of small carriers using diagnostics to protect their bottom line Why shops and dealers don't want you to have this tech (but you should anyway) If you've ever been stranded with a blinking check engine light and no answers, this is the episode that might just save you thousands. ⁠Follow The Long Haul Podcast⁠ ⁠Other FreightWaves Shows⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter tackles a wide-ranging set of listener questions spanning lifespan interventions, exercise, cardiovascular risk reduction, time-restricted eating, blood pressure management, hormone therapy, diagnostics, and more. Peter reveals the single most important lever for extending healthspan and lifespan, and explains how he motivates midlife patients using the Centenarian Decathlon framework. He discusses the importance of addressing high apoB and cholesterol even in metabolically healthy individuals with calcium scores of zero, how to manage high blood pressure, and how to accurately evaluate metabolic health beyond HbA1c. Additional topics include time-restricted eating, practical considerations around ultra-processed foods, nuanced approaches to HRT for women and TRT for men, and why early and expanded screening for chronic disease—colonoscopy, PSA, coronary imaging, low-dose CT—can be lifesaving. He also offers insights into treating prediabetes, crafting exercise programs for those short on time, and safely incorporating high-intensity training in older adults. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #78 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Introducing a wide-ranging AMA: practical perspectives on lifespan interventions, metabolic health, diet, hormones, diagnostics, and more [2:45]; Why exercise is the most powerful single intervention for lifespan and healthspan [4:15]; How Peter motivates midlife patients to prioritize exercise [6:00]; Why lifespan and healthspan should not be treated as competing priorities and how choosing sustainable interventions benefits both [9:30]; Why high apoB deserves treatment even in a metabolically healthy patient with a CAC score of zero [14:00]; Managing hypertension: ideal targets for blood pressure, lifestyle levers, and why early pharmacology matters [18:15]; Assessing metabolic health beyond HbA1c: fasting insulin, triglycerides, lactate, zone 2, and more [23:30]; How to avoid common self-sabotaging patterns by choosing sustainable habits over extreme health interventions [26:00]; Time-restricted eating: minimal effect beyond calorie control, implications for protein intake, and practical considerations for implementing it [28:00]; Ultra-processed foods: definitions, real-world risks, and practical guidelines for smarter consumption [30:30]; How women should prepare for menopause and think about hormone replacement therapy: early planning, symptom awareness, and guidance on HRT [36:45]; Testosterone replacement for aging men: indications, benefits, and safe clinical management [39:45]; Why Peter recommends earlier and more aggressive screening tests than guidelines suggest: colonoscopies, coronary imaging, PSA, Lp(a), and low-dose CT scans, and more [43:30]; Full-body MRI screening: benefits, limitations, potential false positives, and the importance of physician oversight [47:15]; Prediabetes: individualized treatment strategies using tailored combinations of nutrition, sleep, and training interventions [51:00]; Time-efficient training plans for people with only 30 minutes per day to exercise [53:00]; How to safely introduce high-intensity exercise for older adults [55:00]; Timed dead hangs and ripping phone books: a playful look at Peter's early attempts to impress his wife [57:15]; Peter's carve out: The Four Kings documentary about a golden era of boxing [1:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube